NCT07538570PHASE4Recruiting

Evaluation of Pain Treatment After Total Knee Arthroplasty

Vertex Pharmaceuticals Incorporated

Start Date

4/24/2026

Completion Date

1/30/2027

Summary

The purpose of the study is to characterize opioid use after total knee arthroplasty (TKA).

Eligibility Criteria

Age Range: 18 years to 80 years

Key Inclusion Criteria: * Body mass index (BMI) of greater than or equal to (≥) 18.0 to less than or equal to (≤) 40.0 kilogram per meter square (kg/m\^2) * Scheduled to undergo an elective primary unilateral TKA surgery Key Exclusion Criteria: \- History of previous TKA surgery on incident side Other protocol defined Inclusion/Exclusion criteria will apply.

Interventions

DRUG

Suzetrigine

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Pain

Locations

Legent Orthopedic and Spine Hospital

Bellaire, Texas 77401

United States

Memorial Hermann Village Office

Houston, Texas 77043

United States

Run studies, or work at a research site?

Corterve helps sites and sponsors reach patients who are looking for trials. It does not determine eligibility and does not promise an enrolment outcome.

For sponsors, CROs and sites

What Corterve sells to organisations, and the anti-kickback constraints it works within.

Services and published prices

Lay summaries for EU CTR Annex V, pre-screen filtration, recruitment-creative regulatory operations, feasibility reporting.

For research sites

One published licence rate, the same for every site, and the fees a site is never charged.